Eras of transformation each have a foundational layer. Software. The internet. Mobile. Cloud. AI.
The next one may be something many executives still treat as niche: biology made usable through digital systems.
A profound shift appears to be underway. Advances in AI, computation, imaging, sensors, and biological data can make living systems more measurable and modelable. Advances can increasingly make it more designable. Biology is starting to look less like an opaque natural constraint and more like a domain that can be translated into data, prediction, and action.
When something becomes measurable and modelable, it can stop being only a scientific question and become a business question.
For decades, executives generally thought about digital transformation in familiar terms: customer journeys, cloud migration, automation, analytics. Those tools tended to reshape how organizations operate and decide. Ultimately, digital transformation can reshape how they compete. But most of that transformation focused on digitizing work, commerce, and information flows through various systems and stakeholders.
Digital biology points somewhere deeper: digital systems moving into living systems themselves.
INTERPRET COMPLEXITY THROUGH CODE
Historically, many companies had to study, accommodate, or regulate around biology. Drug development tends to be costly and uncertain. Care delivery could vary widely. Many biological questions involved years of experimentation to yield usable insight.
While biology’s inherent complexity remains, the ability to interpret that complexity through code can make biology more digitally legible.
When that happens, the implications can reach far beyond biotech. Health systems can redesign care around prediction and personalization. Medtech companies can build devices that adapt to biological feedback in real time. Businesses and organizations may all find themselves operating closer to biological intelligence as the line between health, data, and everyday life continues to blur.
Digital biology is likely to start resembling prior platform shifts. Software helped to make business processes automatable. AI can make knowledge work generative. Digital biology may do something similar for living systems.
CONSIDERATIONS FOR LEADERS
When a new technology wave emerges, the first question is usually what tools to buy. It’s understandable, but also it tends to be incomplete.
A new survey by the Scottsdale Institute and Deloitte shared that while health system executives overwhelmingly agree that measuring technology value is critical, most still default to traditional metrics like implementation costs—leaving outcomes that matter to consumers, clinicians, and boards routinely undermeasured. Meanwhile, the executives scored themselves at 2.7 out of 5 on their organizations leveraging AI at scale. The ambition appears to be there. The execution infrastructure does not. This is what we call the “tech value gap”—and it could widen further as the stakes rise.
Tools rarely create durable advantage on their own. The winners of the last digital era were generally the ones who redesigned workflows, restructured incentives, integrated data, and rebuilt decision-making around what the technology made possible. They likely didn’t add new tools to old assumptions. They changed the assumptions.
Digital biology is likely to work the same way. Companies pulling ahead may connect biological insight to real business outcomes: better care pathways, smarter products, faster innovation loops.
The medtech sector offers an early signal of both the opportunity and the gap. Deloitte estimates that generative AI could translate to cost efficiencies in medtech companies of 6% to 12% of total revenue over the next two to three years. Capturing that value could involve deploying the technology but also building the organizational capacity to absorb and act on what it produces.
That is a leadership challenge and a scientific one. A 2025 Deloitte and Scottsdale Institute survey of health system C-suite executives found that 61% identified leadership alignment and collaboration as the single top driver of successful technology initiatives. Not the technology itself—the alignment around it. Organizations that treat digital biology as a procurement decision rather than a transformation imperative are likely to find themselves with powerful tools and modest results.
And trust in digital systems matters as much as innovation. When digital systems interpret biology, guide interventions, or shape decisions affecting human health, speed alone may not be enough. Evidence can matter. Transparency and accountability of systems can matter. Deloitte’s 2024 Health Care Consumer Survey reflects the sentiment: 30% of consumers surveyed reported that they do not trust information provided by generative AI, and 80% want to be informed when their doctor uses the technology to make decisions. In this domain, trust should be part of the product, part of the business model, and increasingly, part of the moat. The organizations that pair innovation with evidence and safeguards may be well positioned to earn adoption and scale responsibly.
Not every company is becoming a biology company. But more may find that biology increasingly shapes how they innovate, personalize, and grow.
The leaders who recognize that early may help define the next era of business.
Jay Bhatt is managing director of Deloitte Services LP.